Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Nutriband Inc.

At Nutriband and our subsidiaries,  our core focus is to use innovative drug delivery systems and devices to improve patient outcomes, specifically targeting the Global Opioid epidemic. Fentanyl and other opioid based transdermal medications unfortunately play a role in a significant number of opioid deaths each year with no solution currently available. Working with our Clinical subsidiary 4P Therapeutics we have developed a technology called AVERSA which we believe with FDA approval will revolutionize the safety standard for these medications and save countless lives per year.

Check out our latest coverage in USA Today discussing #AVERSA
#NTRB #opioidepidemic

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting



Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st



Nutriband CEO, Gareth Sheridan, Publishes Letter to Shareholders



Nutriband Signs Commercial Development and Clinical Supply Agreement with Kindeva Drug Delivery for Aversa™ Fentanyl, an Abuse Deterrent Fentanyl Patch

https://lnkd.in/eATne336

NASDAQ:NTRB

Nutriband

Last Close

3.46

03/05 20:00

Market Cap

20.76M

Beta: −0.01

Volume Today

8.75K

Avg: 10.42K

PE Ratio

−4.15

PFCF: −6.01

locale

market

industry

website

crunchbase

linkedin

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics